Crinetics Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRNX research report →
About the company
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist.
- CEO
- R. Scott Struthers
- IPO
- 2018
- Employees
- 437
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $4.45B
- P/E
- -8.22
- P/S
- 246.43
- P/B
- 3.43
- EV/EBITDA
- -8.91
- Div Yield
- 0.00%
- Gross Margin
- 98.89%
- Op Margin
- -3020.32%
- Net Margin
- -2747.18%
- ROE
- -43.96%
- ROIC
- -40.83%
- Revenue
- $7.70M · 640.71%
- Net Income
- $-465,317,000 · -55.93%
- EPS
- $-4.95 · -34.15%
- Op Income
- $-516,769,000
- FCF YoY
- -66.95%
- 52W High
- $57.99
- 52W Low
- $25.83
- 50D MA
- $36.79
- 200D MA
- $41.84
- Beta
- 0.23
- Avg Volume
- 1.23M
Get TickerSpark's AI analysis on CRNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Deardorf Caren | other | 5,925 |
| Jun 18, 26 | Deardorf Caren | other | 9,730 |
| Jun 18, 26 | Fust Matthew K | other | 5,925 |
| Jun 18, 26 | Fust Matthew K | other | 9,730 |
| Jun 18, 26 | Nichols Weston | other | 5,925 |
| Jun 18, 26 | Nichols Weston | other | 9,730 |
| Jun 18, 26 | Vivaldi Coelho Rogerio | other | 5,925 |
| Jun 18, 26 | Vivaldi Coelho Rogerio | other | 9,730 |
| Jun 18, 26 | Bedrosian Camille L | other | 5,925 |
| Jun 18, 26 | Bedrosian Camille L | other | 9,730 |
Our CRNX coverage
Recent articles, reports, and earnings notes.
No research on CRNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRNX report →Similar companies
Peers in the same neighborhood.